William Garrett Nichols

CIK: 0001618364

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)6 (50.0%)

Position reduction

Option Exercises (M)4 (33.3%)

Derivative conversions

Awards (A)2 (16.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

CADL

Candel Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (12 total)

CADL
Candel Therapeutics, Inc.
Jan 26, 2026
Award(A)
Stock Option (Right to Buy)
Direct
136.5K shares-
CADL
Candel Therapeutics, Inc.
Jul 28, 2025
Sale(S)
Direct
937 shares at avg. $6.98$7K
CADL
Candel Therapeutics, Inc.
Jul 28, 2025
Exercise(M)
Direct
937 shares at avg. $1.29$1K
CADL
Candel Therapeutics, Inc.
Jun 30, 2025
Sale(S)
Direct
781 shares at avg. $5.04$4K
CADL
Candel Therapeutics, Inc.
Jun 30, 2025
Exercise(M)
Direct
781 shares at avg. $1.29$1K
CADL
Candel Therapeutics, Inc.
Mar 18, 2025
Sale(S)
Direct
45.3K shares at avg. $8.76$397K
CADL
Candel Therapeutics, Inc.
Mar 18, 2025
Exercise(M)
Direct
4.6K shares at avg. $3.75$17K
CADL
Candel Therapeutics, Inc.
Mar 18, 2025
Exercise(M)
Direct
13.9K shares at avg. $1.29$18K
CADL
Candel Therapeutics, Inc.
Feb 12, 2025
Award(A)
Stock Option (Right to Buy)
Direct
107.3K shares-
CADL
Candel Therapeutics, Inc.
Jan 15, 2025
Sale(S)
Direct
10.4K shares at avg. $7.22$75K
CADL
Candel Therapeutics, Inc.
Jan 8, 2025
Sale(S)
Direct
10.8K shares at avg. $8.22$89K
CADL
Candel Therapeutics, Inc.
Nov 29, 2024
Sale(S)
Direct
13.9K shares at avg. $4.56$63K

		Type	Shares	Price		Ownership
Jan 26, 2026	CADL Candel Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	136,500	-	-	Direct
Jul 28, 2025	CADL Candel Therapeutics, Inc.	Sale(S)	937	$6.98	$6,540	Direct
Jul 28, 2025	CADL Candel Therapeutics, Inc.	Exercise(M)	937	$1.29	$1,209	Direct
Jun 30, 2025	CADL Candel Therapeutics, Inc.	Sale(S)	781	$5.04	$3,936	Direct
Jun 30, 2025	CADL Candel Therapeutics, Inc.	Exercise(M)	781	$1.29	$1,007	Direct
Mar 18, 2025	CADL Candel Therapeutics, Inc.	Sale(S)	45,316	$8.76	$396,995	Direct
Mar 18, 2025	CADL Candel Therapeutics, Inc.	Exercise(M)	4,584	$3.75	$17,190	Direct
Mar 18, 2025	CADL Candel Therapeutics, Inc.	Exercise(M)	13,905	$1.29	$17,937	Direct
Feb 12, 2025	CADL Candel Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	107,250	-	-	Direct
Jan 15, 2025	CADL Candel Therapeutics, Inc.	Sale(S)	10,428	$7.22	$75,342	Direct
Jan 8, 2025	CADL Candel Therapeutics, Inc.	Sale(S)	10,799	$8.22	$88,749	Direct
Nov 29, 2024	CADL Candel Therapeutics, Inc.	Sale(S)	13,935	$4.56	$63,482	Direct

1-12 of 12 transactions

About Nichols William Garrett

Nichols William Garrett (SEC CIK 0001618364) files insider reports with the SEC as Chief Medical Officer of Candel Therapeutics, Inc. (CADL).

Signal8 holds 8 ownership filings by Nichols William Garrett, all Form 4s, filed between Dec 3, 2024 and Jan 28, 2026. Those filings report 12 transactions, from Nov 29, 2024 to Jan 26, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Nichols William Garrett's filings is in NEEDHAM, MA.

Recent filings by Nichols William Garrett

Jan 26, 2026: Grant or award of CADL derivative securities (Form 4, code A).
Jul 28, 2025: Open-market sale of CADL shares (Form 4, code S).
Jul 28, 2025: Option exercise of CADL shares (Form 4, code M).
Jun 30, 2025: Open-market sale of CADL shares (Form 4, code S).
Jun 30, 2025: Option exercise of CADL shares (Form 4, code M).

Other insiders filing for Candel Therapeutics, Inc. (CADL)

Loggia Nicoletta, Director
PAPA JOSEPH C, Director
Manning Paul B, Director
Tak Paul Peter, Chief Executive Officer
Zimmermann Martine, Director
Tyagarajan Seshu, Chief Technology Officer

How to read Form 4 transaction codes